Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat

Item

http://www.wikidata.org/entity/Q37238884

Q37238884

about

Graft-versus-host disease: why have we not made more progress?Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Mesenchymal stromal cells: a new tool against graft-versus-host disease?The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation.Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.

P2860

Q27012940-766DCDD8-9DD7-4855-AEDD-B5B59CBC2984 Q33653406-6E08A4D7-8091-49FB-957E-A7BE38B33E89 Q34044024-05A0765A-4B5F-4B1C-AABB-1DCF475551AC Q34079116-C444577F-5235-4B81-B52E-AAA9F6AF44CF Q34272554-181A705E-1866-4818-AE41-0BB2809F0105 Q34827332-918AF453-2F87-4E0D-B842-5855D2F55FF6 Q35115650-5F7BDADB-5285-4F91-8675-BE8397ED1780 Q35218515-DB7AA703-8AD8-4D4E-B896-0F54BE681921 Q35231363-D6DA240F-2F4C-4F80-B960-9F6AE715A3C9 Q35231368-4C27DC3D-5EE3-44C5-95F9-D21A0C1E4CA0 Q35848391-CFC1FEE0-4EF0-4231-B938-FA993D4ED47D Q36734547-A22A9748-C387-4113-B7DA-FCD453F11F07 Q36761521-3ED7DEBB-8CA1-459E-8FC0-D92F40E69E49 Q36777485-CB47E258-4C51-4AAB-A409-706D327D71AD Q36862464-5E7B8370-1686-4829-97A9-B7DD5A3A589B Q37621636-C0F77AF6-8876-4CDA-AC09-34AB2761C645 Q38105635-9DBCB41A-7307-43C9-A793-A6B1E9AE525E Q38194133-F19F014B-3213-4915-9DD0-4A9B91776540 Q38202155-E859AFC1-C3C1-4882-B177-BCBD00EFC6C1 Q38413246-BB6236C9-4EDE-47C7-BEC9-EEFFE2203E98 Q40834681-FEC49D7E-C75C-4817-8A2E-196ADD3B1DA5 Q41663868-3FE9E7B8-0532-470E-B5D9-AC792B44C3E9 Q48261069-6782F721-EB1A-43F9-803A-3A8E43FAC9E6

P2860

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat

Item

http://www.wikidata.org/entity/Q37238884

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs